Negara: Inggris
Bahasa: Inggris
Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)
Ranitidine hydrochloride
Vantage
A02BA02
Ranitidine hydrochloride
75mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 01030100
PACKAGE LEAFLET: INFORMATION FOR THE USER RANITIDINE 75 MG FILM-COATED TABLETS ranitidine (as hydrochloride) For use in adults and adolescents from 16 years of age READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse after 14 days. WHAT IS IN THIS LEAFLET 1. What _Ranitidine 75 mg_ is and what it is used for 2. What you need to know before you take _Ranitidine 75 mg_ 3. How to take _Ranitidine 75 mg_ 4. Possible side effects 5. How to store _Ranitidine 75 mg_ 6. Contents of the pack and other information 1. WHAT _RANITIDINE 75 MG_ IS AND WHAT IT IS USED FOR _Ranitidine 75 mg _ belongs to a group of medicines known as H 2 -receptor antagonists which reduce the amount of acid in your stomach. _Ranitidine 75 mg_ is used for the short-term, symptomatic treatment of heartburn. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE _RANITIDINE 75 MG_ DO NOT TAKE _RANITIDINE 75 MG_: - if you are allergic (hypersensitive) to Ranitidine or any of the other ingredients of this medicine (listed in section 6). _ _ _Ranitidine 75 mg_ may not be given to children under 16 years of age. WARNING AND PRECAUTIONS Talk to your doctor or pharmacist before taking _ Ranitidine 75 mg_ : - if you have ever suffered from a stomach or intestinal ulcer. - if you are inadvertently losing weight in association with existing indigestion problems. - if you suffer from kidney or liver problems, or any other illness which requires regular medical supervision. - if you suffer from any other illness, or are taking other medicines, that your doctor has Baca dokumen lengkapnya
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ranitidine 75mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 83.75 mg of ranitidine hydrochloride equivalent to 75 mg of ranitidine. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Light pink, round, biconvex, film-coated tablets with embossment “75” on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ranitidine Tablets are indicated for the short-term symptomatic relief of heartburn. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults (including the elderly) and adolescents of 16 years of age and older. One Ranitidine 75mg tablet should be taken when symptoms occur, day or night. Do not take more than two tablets in 24 hours. Patients will be instructed not to take the tablets for more than 2 weeks continuously. They must consult their doctor if symptoms deteriorate or persist after 2 weeks treatment. Children under 16 years. The tablets are not recommended for children under 16 years of age. 4.3 CONTRAINDICATIONS • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • Ranitidine tablets should not be given to children under 16 years of age. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE The possibility of malignancy should be excluded before commencement of therapy in patients with gastric ulcer as treatment with ranitidine may mask symptoms of gastric carcinoma. Ranitidine is excreted via the kidney and so plasma levels of the drug are increased in patients with renal impairment. Rare clinical reports suggest that ranitidine may precipitate acute porphyric attacks. Ranitidine should therefore be avoided in patients with a history of acute porphyria. In patients such as the elderly, persons with chronic lung disease, diabetes or the immunocompromised, there may be an increased risk of developing community acquired pneumonia. A large epidemiological study showed an increased risk of developing community acquired pneumonia in cur Baca dokumen lengkapnya